Rohto Pharma (India) Private Limited Revenue and Competitors
Estimated Revenue & Valuation
- Rohto Pharma (India) Private Limited's estimated annual revenue is currently $5M per year.
- Rohto Pharma (India) Private Limited's estimated revenue per employee is $100,500
Employee Data
- Rohto Pharma (India) Private Limited has 50 Employees.
- Rohto Pharma (India) Private Limited grew their employee count by 11% last year.
Rohto Pharma (India) Private Limited's People
Name | Title | Email/Phone |
---|
Rohto Pharma (India) Private Limited Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $56.6M | 563 | 21% | N/A | N/A |
#2 | $15.6M | 155 | 28% | N/A | N/A |
#3 | $17M | 169 | -11% | N/A | N/A |
#4 | $13.2M | 131 | 8% | N/A | N/A |
#5 | $19.6M | 195 | 10% | N/A | N/A |
#6 | $23.5M | 234 | 7% | N/A | N/A |
#7 | $5.3M | 53 | 0% | N/A | N/A |
#8 | $13M | 129 | -25% | N/A | N/A |
#9 | $20.5M | 204 | 11% | N/A | N/A |
#10 | $11.7M | 116 | 6% | N/A | N/A |
What Is Rohto Pharma (India) Private Limited?
Rohto Pharma (India) Pvt. Ltd. is a subsidiary of ROHTO Pharmaceutical Co., Ltd. in Osaka, Japan, specialised in the wide range of business domain of Consumer Healthcare. ROHTO was established in 1899. Since then it remains as a trusted brand in Japan and Asia. Mentholatum was founded in 1889 in US. It is a century-old household name in US. Rohto Pharma (India) represents ROHTO and Mentholatum brands in the region. The some of main products of Rohto and Mentholatum brands are; EYE CARE - ROHTO V eyedrops - ROHTO C-Cube eyedrops - ROHTO Anti-bacterial eyedrops - ROHTO Kodomo eyedrops SKIN CARE - Hadalabo - OXY - Acnes LIP CARE - LipIce - Softlips - Natural Ice Gastro-Intestinal Medicines - Pansiron - Wakansen
keywords:N/AN/A
Total Funding
50
Number of Employees
$5M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.4M | 50 | -17% | N/A |
#2 | N/A | 50 | -11% | N/A |
#3 | $4.8M | 51 | 55% | N/A |
#4 | $6.1M | 52 | N/A | N/A |
#5 | $3.4M | 52 | 30% | N/A |